We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Approximately 55 per cent of type T2D patients suffer from cardiovascular disease (CVD), which often leads to further complications such as major adverse cardiac events.